PACE-CME.org was present at the ESC 2017 in Barcelona. Find coverage of the latest CV news on PACE-CME.
ESC 2017 Dr. Wilko Spiering summarises the results of the CALM-FIM study, showing that endovascular baroreflex amplification with MobiusHD device lowers BP in resistant hypertension.
ESC 2017 Clyde Yancy summarises insights of studies presented at the ESC on managment of hypertension and associated CV risk, which can help understanding of how treatment can be improved.
Inflammation Expert Opinions Lina Badimon explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation. The results of CANTOS can be the dawn of a new era of CV prevention.
ESC 2017 A patient-level pooled analysis of REMINDER and ALBATROSS data suggests that there may be a mortality benefit of treating STEMI patients with a mineralocorticoid receptor antagonist.
Inflammation Expert Opinions Erik Stroes summarizes the results from CANTOS and states that for daily clinical practice, it is important to select the major factors contributing to CV risk
Inflammation Expert Opinions Filippo Crea riflette su una pubblicazione del 1994, introducendo l’ ipotesi sull’infiammazione e spiega come lo studio CANTOS confermi tale ipotesi. La sfida ora è individuare i pazienti che trarranno beneficio da questo trattamento.
Inflammation Expert Opinions Paul Ridker and Peter Libby look back at the evolution of their research efforts on the role of inflammation in CV risk, and how they saw their hypothesis confirmed in the CANTOS trial.
ESC 2017 One of the ESC Grand Debates revolved around whether or not aspirin should be used for primary and/or secondary CV prevention. Yes, there is a lot of evidence, but how valid is that evidence? Read an impression of this Grand Debate held at ESC 2017.
ESC 2017 The SPYRAL-HTN study showed encouraging results with renal denervation in a sham-controlled trial. Blood pressure was reduced in patients not requiring medication for their hypertension.
ESC 2017 In the REVEAL study, four years after treatment with the CETP inhibitor anacetrapib in addition to high-dose statin, a 9% reduction of the primary endpoint was seen in CVD patients.
ESC 2017 Data of the large long-term world-wide population study PURE show that 3-4 portions of vegetables and fruit is optimal and fat intake up to 30-35% of calories per day is healthy, irrespective of the type of fat.
ESC 2017 Fewer major bleedings with dual therapy of dabigatran and platelet inhibitor than with triple therapy with warfarin, platelet inhibitor and aspirin, in AF patients receiving a stent in RE-DUAL PCI..